Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jun;10(6):721-723.
doi: 10.1016/j.jacbts.2025.04.005.

Do Anti-PCSK9 Monoclonal Antibodies Have Pleiotropic Effects?

Nicola Ferri  1
Affiliations
Editorial

Do Anti-PCSK9 Monoclonal Antibodies Have Pleiotropic Effects?

Nicola Ferri. JACC Basic Transl Sci. 2025 Jun.
No abstract available

Keywords: (18)F-FDG-PET imaging; PCSK9 inhibition; acute myocardial infarction; myocardial inflammation.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Ferri has received honoraria from Pfizer, Amgen, Daiichi Sankyo, Bristol Myers Squibb, Relmada Therapeutics, and Pharmanutra.

Figures

None
Graphical abstract
See this image and copyright information in PMC

Comment on

  • doi: 10.1016/j.jacbts.2025.03.010

Similar articles

See all similar articles

References

    1. Byrne R.A., Rossello X., Coughlan J.J., et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–3826. - PubMed
    1. Ziogos E., Harb T., Valenta I., et al. Impact of in-hospital PCSK9 inhibition on myocardial inflammation after myocardial infarction: a randomized clinical trial. JACC Basic Transl Sci. 2025;10(6):709–720. - PubMed
    1. Gargiulo P., Basile C., Galasso G., et al. Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry. Eur J Prev Cardiol. 2024;31:1806–1816. - PubMed
    1. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38. - PubMed
    1. Leucker T.M., Blaha M.J., Jones S.R., et al. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial. Circulation. 2020;142:419–421. - PMC - PubMed

Publication types

LinkOut - more resources